Universitätspublikationen
Filtern
Dokumenttyp
- Wissenschaftlicher Artikel (20)
- Dissertation (2)
Sprache
- Englisch (22) (entfernen)
Volltext vorhanden
- ja (22) (entfernen)
Gehört zur Bibliographie
- nein (22)
Schlagworte
- Mitochondria (22) (entfernen)
The filamentous ascomycete Podospora anserina is a well-established model system to study organismic aging. Its senescence syndrome has been investigated for more than fifty years and turned out to have a strong mitochondrial etiology. Several different mitochondrial pathways were demonstrated to affect aging and lifespan. Here, we present an update of the literature focusing on the cooperative interplay between different processes.
Background: Protein translocation across membranes is a central process in all cells. In the past decades the molecular composition of the translocation systems in the membranes of the endoplasmic reticulum, peroxisomes, mitochondria and chloroplasts have been established based on the analysis of model organisms. Today, these results have to be transferred to other plant species. We bioinformatically determined the inventory of putative translocation factors in tomato (Solanum lycopersicum) by orthologue search and domain architecture analyses. In addition, we investigated the diversity of such systems by comparing our findings to the model organisms Saccharomyces cerevisiae, Arabidopsis thaliana and 12 other plant species.
Results: The literature search end up in a total of 130 translocation components in yeast and A. thaliana, which are either experimentally confirmed or homologous to experimentally confirmed factors. From our bioinformatic analysis (PGAP and OrthoMCL), we identified (co-)orthologues in plants, which in combination yielded 148 and 143 orthologues in A. thaliana and S. lycopersicum, respectively. Interestingly, we traced 82% overlap in findings from both approaches though we did not find any orthologues for 27% of the factors by either procedure. In turn, 29% of the factors displayed the presence of more than one (co-)orthologue in tomato. Moreover, our analysis revealed that the genomic composition of the translocation machineries in the bryophyte Physcomitrella patens resemble more to higher plants than to single celled green algae. The monocots (Z. mays and O. sativa) follow more or less a similar conservation pattern for encoding the translocon components. In contrast, a diverse pattern was observed in different eudicots.
Conclusions: The orthologue search shows in most cases a clear conservation of components of the translocation pathways/machineries. Only the Get-dependent integration of tail-anchored proteins seems to be distinct. Further, the complexity of the translocation pathway in terms of existing orthologues seems to vary among plant species. This might be the consequence of palaeoploidisation during evolution in plants; lineage specific whole genome duplications in Arabidopsis thaliana and triplications in Solanum lycopersicum.
Mitochondrial dysfunction is well documented in presymptomatic brain tissue with Parkinson's disease (PD). Identification of the autosomal recessive variant PARK6 caused by loss-of-function mutations in the mitochondrial kinase PINK1 provides an opportunity to dissect pathogenesis. Although PARK6 shows clinical differences to PD, the induction of alpha-synuclein "Lewy" pathology by PINK1-deficiency proves that mitochondrial pathomechanisms are relevant for old-age PD. Mitochondrial dysfunction is induced by PINK1 deficiency even in peripheral tissues unaffected by disease, consistent with the ubiquitous expression of PINK1. It remains unclear whether this dysfunction is due to PINK1-mediated phosphorylation of proteins inside or outside mitochondria. Although PINK1 deficiency affects the mitochondrial fission/fusion balance, cell stress is required in mammals to alter mitochondrial dynamics and provoke apoptosis. Clearance of damaged mitochondria depends on pathways including PINK1 and Parkin and is critical for postmitotic neurons with high energy demand and cumulative stress, providing a mechanistic concept for the tissue specificity of disease.
Mitochondria perform essential energetic, metabolic and signalling functions within the cell. To fulfil these, the integrity of the mitochondrial proteome has to be preserved. Therefore, each mitochondrial subcompartment harbours its own system for protein quality control. However, if the capacity of mitochondrial chaperones and proteases is overloaded, mitochondrial misfolding stress (MMS) occurs. Upon this stress condition, mitochondria communicate with the nucleus to increase the transcription of nuclear encoded mitochondrial chaperones and proteases. This proteotoxic stress pathway was termed the mitochondrial unfolded protein response (UPRmt) aiming at restoring protein homeostasis. Despite being discovered over 25 years ago, the signalling molecules released by stressed mitochondria as well as the corresponding receptor and transcription factor remain poorly understood. With this study, we aimed at characterising the underlying signalling events and mechanisms of how mitochondria react to misfolded proteins. First, we aimed to establish different methods to induce MMS that triggers the transcriptional induction of mitochondrial chaperones and proteases detected by quantitative polymerase chain reaction. We were able to induce UPRmt signalling by overexpression of an aggregation-prone protein and by knock-down or inhibition of mitochondrial protein quality control components. To study the signalling in a time-resolved manner, we focused on the usage of the mitochondrial HSP90 inhibitor GTPP and the mitochondrial LONP1 protease inhibitor CDDO.
Early time point RNA sequencing analysis of cells stressed with GTPP or CDDO revealed upregulated genes in response to oxidative stress. Indeed, measurements of mitochondrial superoxide with the fluorescent dye MitoSOX showed increased levels of reactive oxygen species (ROS) upon MMS induction. In contrast, there was no induction of mitochondrial chaperones and proteases when combining MMS with antioxidants. Compartment-specific targeting of the hydrogen peroxide sensor HyPer7 revealed increased ROS levels in the intermembrane space and matrix of mitochondria, followed by elevated ROS levels in the cytosol at later time points. The importance of cytosolic ROS for the signalling was supported by preventing UPRmt induction with an inhibitor blocking the outer mitochondrial membrane pore. Thus, ROS were identified as an essential UPRmt signal.
To understand which cytosolic factor is modified by ROS, redox proteomics was performed. Here, reversible changes on cysteine residues of the HSP40 co-chaperone DNAJA1 were observed upon MMS. Consequently, transcriptional induction of UPRmt genes was abolished by DNAJA1 knock-down. To understand the function of DNAJA1 during UPRmt signalling, quantitative interaction proteomics upon MMS revealed an increased binding to mitochondrial proteins and its interaction partner HSP70. Immunoprecipitation confirmed a ROS-dependent interaction between HSP40 and HSP70. Increased binding to mitochondrial proteins represented a cytosolic interaction of DNAJA1 with mitochondrial precursor proteins, whose accumulation was confirmed by western blot. Moreover, a fluorescent protein targeted to mitochondria accumulated in the cytosol during GTPP treatment, confirming a reduced import efficiency upon MMS. Preventing the accumulation of precursors by a translation inhibitor or depletion of a general mitochondrial transcription factor resulted in reduced UPRmt activation. Thus, DNAJA1 is essential for UPRmt signalling, since its oxidation by mitochondrial ROS and its enhanced recruitment to mitochondrial precursors allows the integration of both MMS-induced signals.
To link these findings to an increased transcription of mitochondrial chaperones and proteases, we screened for transcription factors accumulating in the nucleus upon MMS by cellular fractionation mass spectrometry. We demonstrated that specifically HSF1 accumulates in nuclei of cells stressed with GTPP or CDDO. Depletion of HSF1 by knock-down or knock-out resulted in the abrogation of the UPRmt-specific transcriptional response. HSF1 activation was visualised by nuclear accumulation on western blot, a process inhibited by ROS and precursor suppression. Moreover, DNAJA1 depletion prevented HSF1 activation. Ultimately, we proved by immunoprecipitation that the inhibitory interaction between HSF1 and HSP70 is reduced upon MMS.
Thus, we conclude that MMS increases mitochondrial ROS that are released into the cytosol. In addition, the import efficiency is reduced upon MMS, resulting in the accumulation of non-imported mitochondrial precursor proteins in the cytosol. Both signals are recognised via DNAJA1 oxidation and substrate binding. The concurrent recruitment of HSP70 to DNAJA1 results in the loss of the inhibitory HSP70-HSF1 interaction. Thus, active HSF1 can migrate to the nucleus to initiate transcription of mitochondrial chaperones and proteases. These findings are in accordance with observations in yeast, where mistargeted mitochondrial proteins activate cellular stress responses. Our results highlight a surprising interconnection and dependence of the mitochondrial and the cytosolic proteostasis network, in which the UPRmt is activated by a combination of two mitochondria-specific proteotoxic stress signals.
Background: Alzheimer’s disease (AD) is the most common form of dementia, and it affects more women than men. Mitochondrial dysfunction (MD) plays a key role in AD, and it is detectable at an early stage of the degenerative process in peripheral tissues, such as peripheral mononuclear blood cells (PBMCs). However, whether these changes are also reflected in cerebral energy metabolism and whether sex-specific differences in mitochondrial function occur are not clear. Therefore, we estimated the correlation between mitochondrial function in PBMCs and brain energy metabolites and examined sex-specific differences in healthy participants to elucidate these issues.
Methods: The current pilot study included 9 male and 15 female healthy adults (mean age 30.8 ± 7.1 years). Respiration and activity of mitochondrial respiratory complexes were measured using a Clarke-electrode (Oxygraph-2k system), and adenosine triphosphate (ATP) levels were determined using a bioluminescence-based assay in isolated PBMCs. Citrate synthase activity as a mitochondrial marker was measured using a photometric assay. Concentrations of brain energy metabolites were quantified in the same individuals using 1H-magnetic resonance spectroscopy (MRS).
Results: We detected sex-associated differences in mitochondrial function. Mitochondrial complexes I, I+II, and IV and uncoupled respiration and electron transport system (ETS) capacity in PBMCs isolated from blood samples of females were significantly (p < 0.05; p < 0.01) higher compared to males. ATP levels in the PBMCs of female participants were approximately 10% higher compared to males. Citrate synthase (CS) activity, a marker of mitochondrial content, was significantly (p < 0.05) higher in females compared to males. Sex-associated differences were also found for brain metabolites. The N-acetylaspartate (NAA) concentration was significantly higher in female participants compared to males in targeted regions. This difference was observed in white matter (WM) and an area with a high percentage (> 50%) of gray matter (GM) (p < 0.05; p < 0.01). The effect sizes indicated a strong influence of sex on these parameters. Sex-associated differences were found in PBMCs and brain, but the determined parameters were not significantly correlated.
Conclusions: Our study revealed sex-associated differences in mitochondrial function in healthy participants. The underlying mechanisms must be elucidated in more detail, but our study suggests that mitochondrial function in PBMCs is a feasible surrogate marker to detect differences in mitochondrial function and energy metabolism in humans and it underscores the necessity of sex-specific approaches in therapies that target mitochondrial dysfunction.
The endoplasmic reticulum–mitochondria encounter structure (ERMES) connects the mitochondrial outer membrane with the ER. Multiple functions have been linked to ERMES, including maintenance of mitochondrial morphology, protein assembly and phospholipid homeostasis. Since the mitochondrial distribution and morphology protein Mdm10 is present in both ERMES and the mitochondrial sorting and assembly machinery (SAM), it is unknown how the ERMES functions are connected on a molecular level. Here we report that conserved surface areas on opposite sides of the Mdm10 β-barrel interact with SAM and ERMES, respectively. We generated point mutants to separate protein assembly (SAM) from morphology and phospholipid homeostasis (ERMES). Our study reveals that the β-barrel channel of Mdm10 serves different functions. Mdm10 promotes the biogenesis of α-helical and β-barrel proteins at SAM and functions as integral membrane anchor of ERMES, demonstrating that SAM-mediated protein assembly is distinct from ER-mitochondria contact sites.
Mitochondrial respiratory supercomplexes (mtRSCs) are stoichiometric assemblies of electron transport chain (ETC) complexes in the inner mitochondrial membrane. They are hypothesized to regulate electron flow, the generation of reactive oxygen species (ROS) and to stabilize ETC complexes. Using the fungal ageing model Podospora anserina, we investigated the impact of homologues of the Saccharomyces cerevisiae respiratory supercomplex factors 1 and 2 (termed PaRCF1 and PaRCF2) on mtRSC formation, fitness and lifespan. Whereas PaRCF2’s role seems negligible, ablation of PaRCF1 alters size of monomeric complex IV, reduces the abundance of complex IV-containing supercomplexes, negatively affects vital functions and shortens lifespan. PaRcf1 overexpression slightly prolongs lifespan, though without appreciably influencing ETC organization. Overall, our results identify PaRCF1 as necessary yet not sufficient for mtRSC formation and demonstrate that PaRCF1-dependent stability of complex IV and associated supercomplexes is highly relevant for maintenance of the healthy lifespan in a eukaryotic model organism.
To understand neurodegenerative diseases is one of the major challenges of the 21st century. This also includes Alzheimer´s disease (AD), which represents a chronic neurodegenerative disorder, with long preclinical and prodromal phases (approx. 20 years) and an average clinical duration of 8–10 years. In the early phase of this disease, patients show deterioration of memory, difficulties in finding the right words for everyday objects or mood swings. The risk of AD grows exponentially with age, doubling approximately every 5 to 6 years. AD may contribute to 60–70% of all dementia cases, being the most common cause of this disease. Dementia is one of the major causes of disability and dependency among older people worldwide. The causes of the sporadic form of AD with late onset (LOAD) are not yet known, but it seems to be a result of multiple factors. Neuropathological features are extracellular senile plaques, containing beta-amyloid peptides (Aβ) and intracellular neurofibrillary tangles, containing paired helical tau proteins, which have been associated with neuronal loss and atrophy of the cerebral cortex. Thus, misfolded proteins seem to contribute to the pathogenesis, but are not the only players in the disease process. Developing feasible therapies is difficult due to the multifactorial pathology of AD. Currently approved drugs only attenuate symptoms, but do not cure the disease. Research into AD also has had several failures in terms of developing disease-modifying therapies. Thus, new therapeutic targets in order to develop a causal therapy are desperately needed. Since AD starts many years far before the first symptoms occur, new scientific approaches focus on the early stage, which are discussed to be important in aging and the onset of AD. Today, the hypothesis of the advanced mitochondrial cascade becomes more and more the leading model for LOAD, integrating physiological aging as the main risk factor. Thus, new interventions targeting mitochondrial dysfunction are of substantial interest. Accordingly, the efficacy of Dimebon and TRO19622 to ameliorate mitochondrial dysfunction in cellular and murine models of AD were investigated. Dimebon (Latrepirdine) was, originally developed in Russia as an H1-antiallergic drug. It might specifically interfere with mechanisms relevant for the cognitive decline, especially by improving impaired mitochondrial function and/or dynamics in AD. TRO19622 (Olesoxim) has been identified in a phenotypic screening approach to promote the survival of primary motor neurons. Olesoxim is easily absorbed by cells and accumulates in mitochondria. Olesoxim’s mode of action is not fully understood, however it has been shown to modulate mitochondrial membranes and interact with the voltage-dependent anion channel (VDAC) and the translocator protein (TSPO; also known as PBR). Thereby it inhibits mitochondrial permeability transition. In this study, the effects of Aβ overproduction on mitochondrial function were investigated. The effects of Dimebon and Olesoxim were examined, using a HEK cell line stably transfected with the Swedish APP double mutation (HEKsw) and un-transfected control cells (HEKut). Mitochondrial membrane potential, ATP concentrations, and respirometry were measured. Western Blot analysis of marker proteins for fission & fusion, autophagy, mitogenesis and mPTP formation were performed. Confocal laser scanning microscopy was introduced as a novel method to visualize mitochondrial dynamics. Olesoxim was also tested in Thy-1-C57BJ/6-APPSL mice representing a murine model of AD. For the in vivo model mitochondria from brain tissue were isolated and dissociated brain cells were prepared to determine respiration, lipid peroxidation, MMP, and ATP-levels. Both, the in vitro and in vivo models were compared and discussed in relation to human post-mortem data. The research was conducted in frame of the EU-project entitled „MITOTARGET“ (Mitochondrial dysfunction in neurodegenerative diseases: towards new therapeutics) funded under FP7-Health (http://cordis.europa.eu/result/rcn/54471_en.html). HEKsw cells showed an overall reduction in the mitochondrial respiration, a significant lower MMP, and significantly reduced ATP levels compared to HEKut cells. Mitochondrial mass was equal in both cell lines. In addition most mitochondria in HEKsw cells showed truncated morphology, followed by punctuated mitochondria. Levels of the fission related protein Drp were significantly elevated in HEKsw cells whereas protein levels of fusion related OPA were strongly reduced, leading to a shift in the distribution pattern towards shorter mitochondria. Moreover, HEKsw cells showed reduced mitochondrial density. Protein levels of the translocase of the inner mitochondrial membrane (TIMM50) were strongly diminished in HEKsw cells. The OXPHOS machinery is located in the inner membrane, where the MMP is build up and ATP is generated. Reduced TIMM50 levels in HEKsw indicated a reduction of the inner mitochondrial membrane, which could explain the described deficits in OXPHOS, MMP, ATP and mitochondrial morphology and density. Concentration of both mPTP markers, the voltage-depended anion channel (VDAC) and the peripheral benzodiazepine receptor (PBR), were broadly increased in HEKsw cells. Thy1-APPSL transgenic mice were characterized as in vivo model of AD. Those mice are modified to express the human form of APP, containing both, the Swedish (KM670/671NL) and the London (V717L) double mutations under the murine Thy1 promotor. Beginning at the age of 3 months, Thy1-APPSL mice develop elevated Aβ levels and mitochondrial dysfunction. Mitochondria isolated from brains of Thy-1-C57BJ/6-APPSL mice showed significant impaired respiration, resulting in a reduced MMP. However, ATP levels in dissociated brain cells did not differ compared to controls. Protein levels of FIS were unchanged, whereas Drp levels were significantly increased. Levels of the mitochondrial fusion marker optic atrophie-1 (Opa) protein were significantly reduced. Peroxisome proliferation-activated receptor gamma coactivator 1-alpha (PGC1) is a transcription factor, which represents a master regulator of mitochondrial biogenesis. PGC1 expression was significantly elevated in brains of Thy-1-C57BJ/6-APPSL mice. However, mitochondrial mass seemed to be equal in both mouse lines. Both LC3-Isoforms, the cytosolic and the autophagosomal form, were not changed in brains of Thy-1-C57BJ/6-APPSL mice, which indicates equal mitophagic activity. In brain homogenates, isolated from Thy-1-C57BJ/6-APPSL mice, both mPTP marker, VDAC and PBR, were considerably increased, which is in accordance with the findings in HEKsw cells. In conclusion, both, the cellular (HEKsw) and the animal model of AD (Thy1-APPSL) broadly match pathophysiological features, which have been found in post-mortem samples from AD patients. Thus, HEKsw cells and Thy1-APPSL mice seem to be suitable models to study new treatments against AD. Incubation of HEKsw cells with Dimebon resulted in a remarkable increase in respiratory activity and restored the MMP after impairing the cells with rotenon. Dimebon had no effects on ATP levels in both cell lines, neither after challenging cells with rotenon, nor under basal conditions. By adding Dimebon, citrate synthase (CS) activity in HEKsw cells was increased and mitochondrial morphology was shifted to a tubular shape. Dimebon further enhanced protein levels of Drp and resulted in the compensation of reduced OPA levels. Moreover, Dimebon restored the increased expression levels of the mPTP markers VDAC and PBR. Aβ1-40 levels were significantly decreased in HEKsw cells. However, changes in Aβ1-40 levels seemed to be too small, to solely explain the much larger effects of Dimebon on impaired mitochondrial function. In conclusion, Dimebon treatment restored diverse defects in Aβ overexpressing cells: Aβ levels were reduced, autophagy marker were increased, mitophagy as repair and renewal mechanism was elevated, mitochondrial mass and density were increased, OXPHOS capacity was restored, mitochondrial dynamics were balanced, mitochondrial shape showed a normal distribution, expression levels of the mPTP constituents were reduced, TIMM50 levels augmented to control levels and stress induced MMP and ROS levels were reduced. All these effects were observed after incubation of cells with a rather low concentration of 100 nmol/L. Based on these findings and in addition to already existing literature, Dimebon presents a potential therapeutic option for diseases with accompanied mitochondrial dysfunction. Although, clinical findings published so far are inconsistent. Olesoxim induced a general increase in respiratory activity and enhanced the electron transport (ETS) capacity in HEKsw cells. In addition it normalized the OXPHOS activity almost to control levels. However, incubation using different Olesoxim concentrations led to a dose independent decline in the MMP and decreased ATP levels. Adding Olesoxim caused a dose-dependent change in the length of mitochondria strongly shifting the pattern towards longer mitochondria. In HEKsw cells a reduced mitochondrial density was observed which was reversed by Olesoxim dose-dependently. Olesoxim completely compensated the severely reduced expression levels of TIMM50, but had no effects on TOMM22 levels. An unexpected finding was that 10 µM Olesoxim significantly increased Aβ1-40 levels. Effects of Olesoxim were also tested in vivo. Treatment of Thy-1-C57BJ/6-APPSL mice with Olesoxim restored the impaired MMP in dissociated brain cells, but had no effects on ATP-levels. Olesoxim increased the respiratory activity in isolated brain mitochondria and restored impaired respiration complex activities almost to control levels, without having an effect on CS activity. However, treatment with Olesoxim caused an increase of PGC1 protein levels in brains of Thy-1-C57BJ/6-APPSL mice,beyond basal levels of littermate controls. The mPTP marker proteins voltage-depended anion channel (VDAC) and peripheral benzodiazepine receptor (PBR) were significantly reduced. As well as in the cell models, treatment of Thy-1-C57 BJ/6-APPSL mice with Olesoxim significantly enhanced total human, soluble human and soluble mouse Aβ1-40 levels. Further investigation needs the observation that Olesoxim caused partly negative effects in controls. For instance, Olesoxim reduced the OXPHOS capacity and enhanced protein levels of VADAC and PBR in brains of C57BJ/6 littermate control mice, which could limit the applicability of Olesoxim in further preclinical studies.
Background: NH exchangers (NHEs) play a crucial role in regulating intra/extracellular pH, which is altered in cancer cells, and are therefore suitable targets to alter cancer cell metabolism in order to inhibit cell survival and proliferation. Among NHE inhibitors, amiloride family members are commonly used in clinical practice as diuretics; we focused on the amiloride HMA, reporting a net cytotoxic effect on a panel of human cancer cell lines; now we aim to provide new insights into the molecular events leading to cell death by HMA.
Methods: Colon cancer cell lines were treated with HMA and analysed with: morphological and cellular assays for cell viability and death, and autophagy; biochemical approaches to evaluate mitochondrial function and ROS production; in situ detection of DNA damage; molecular tools to silence crucial autophagy/necroptosis factors.
Results: HMA affects cellular morphology, alters mitochondrial structure and function, causes an increase in ROS, which is detrimental to DNA integrity, stimulates poly(ADP-ribose) synthesis, activates RIPK3-dependent death and triggers autophagy, which is unable to rescue cell survival. These features are hot points of an intricate network of processes, including necroptosis and autophagy, regulating the homeostasis between survival and death.
Conclusion: Our results allow the identification of multiple events leading to cell death in cancer cells treated with HMA. The here-defined intricate network activated by HMA could be instrumental to selectively target the key players of each pathway in the attempt to improve the global response to HMA. Our data could be the starting point for developing a newly designed targeted therapy.
Hypoxia triggers several mechanisms to adapt cells to a low oxygen environment. Mitochondria are major consumers of oxygen and a potential source of reactive oxygen species (ROS). In response to hypoxia they exchange or modify distinct subunits of the respiratory chain and adjust their metabolism, especially lowering the citric acid cycle. Intermediates of the citric acid cycle participate in regulating hypoxia inducible factors (HIF), the key mediators of adaptation to hypoxia. Here we summarize how hypoxia conditions mitochondria with consequences for ROS-production and the HIF-pathway.